@aisavvycapital · Long ABSI

BIO-TECH had a strong sell off today (10% or more on many names), so I'm buying afterhours, here is my favs: • ABSI — about $2.0B. Generative AI designs antibodies from scratch, closest to Moderna’s model. Phase 2 endometriosis trial for ABS-201 is set for mid-2027. • RXRX —

Read asLong ABSI+4 more

Since the call—

unrankedThe analyst's rank today

High · 0.99Confidence

Tue, Oct 6Tweeted

Wed, Oct 7 closeCounted from

not in the basket todayBasket

Rank per close

#112

Oct 7

—

Oct 8

#143

Oct 11

#288

Oct 12

—

Oct 13

—

Oct 14

—

Oct 15

—

Oct 18

—

Oct 19